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Background: The PDZ adaptor protein PDZK1 modulates the membrane expression
and function of a variety of intestinal receptors and ion/nutrient transporters. Its
expression is strongly decreased in inflamed intestinal mucosa of mice and IBD patients.
Aim and Methods: We investigated whether the inflammation-associated PDZK1
downregulation is a direct consequence of proinflammatory cytokine release by treating
intestinal Caco-2BBE cells with TNF-α, IFN-γ, and IL-1β, and analysing PDZK1 promotor
activity, mRNA and protein expression.
Results: IL-1β was found to significantly decrease PDZK1 promoter activity, mRNA and
protein expression in Caco-2BBE cells. A distal region of the hPDZK1 promoter was
identified to be important for basal expression and IL-1β-responsiveness. This region
harbors the retinoid acid response element RARE as well as binding sites for transcription
factors involved in IL-β downstream signaling. ERK1/2 inhibition by the specific MEK1/2
inhibitors PD98059/U0126 significantly attenuated the IL-1β mediated downregulation of
PDZK1, while NF-κB, p38 MAPK, and JNK inhibition did not. Expression of the nuclear
receptors RXRα and PPARα was decreased in inflamed colonic-mucosa of ulcerative
colitis patients and in IL-1β-treated Caco2-BBE cells. Moreover, the RAR/RXR ligand
9-cis retinoic acid and the PPARα-agonist GW7647 stimulated PDZK1mRNA and protein
expression and attenuated IL-1β-mediated inhibition.
Conclusions: The strong decrease in PDZK1 expression during intestinal inflammation
may be in part a consequence of IL-1β-mediated RXRα and PPARα repression and
can be attenuated by agonists for either nuclear receptor, or by ERK1/2 inhibition. The
negative consequences of inflammation-induced PDZK1 downregulation on epithelial
transport-function may thus be amenable to pharmacological therapy.
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INTRODUCTION
We recently reported that the expression of the PDZ-adaptor
protein PDZK1 (NHERF3) is strongly reduced in inflamed
intestine of ulcerative colitis patients and murine models
of colitis (Lenzen et al., 2012; Yeruva et al., 2015). One
consequence of the loss of PDZK1 expression is a defective
regulation of the major intestinal sodium absorptive protein
NHE3 (Cinar et al., 2007; Hillesheim et al., 2007; Zachos
et al., 2009), but there are likely other defects, because
PDZK1 binds to and regulates the function of an array of
important intestinal transport proteins (Rossmann et al.,
2005; Li et al., 2007; Sugiura et al., 2008, 2011; Moon
et al., 2015). PDZK1 is an essential adaptor protein for
a number of other important receptors, i.e., the hepatic
HDL/LDL receptor SR-BI, and loss of its function leads
to hypercholesterolemia and atherosclerosis (Kocher and
Krieger, 2009). It also regulates the membrane expression
and function of transporters in other organs, i.e., the urate
transporter URAT (Endou and Anzai, 2008), the oxalate
transporter CFEX (Thomson et al., 2005), and the multidrug
resistance protein MRP4 in the kidney (Park et al., 2014). An
inflammation-associated decrease of PDZK1 may thus be an
important aspect of organ dysfunction in other inflammatory
conditions in the body, and exploration of the molecular
mechanisms of PDZK1 downregulation deserves further
study.
One potential mechanism for the inflammation-associated
decrease in PDZK1 in the intestine could be an alteration
of the cellular composition of the intestinal mucosa or a
change in the differentiation pattern of the enterocytes.
Another potential mechanism could be a direct effect of
proinflammatory mediators on PDZK1 synthesis in the
epithelial cells. As these cytokines were found to be most
consistently upregulated in intestinal tissues from IBD patients
and an array of mouse models for intestinal inflammation
(Dionne et al., 1997; Raddatz et al., 2005; Matsuda et al.,
2009; Yeruva et al., 2010, 2015), we investigated the effect
of TNF-α, IFN-γ [added because it may be necessary for
inducing IL-1β and TNF-α receptors in intestinal epithelial
cells and Caco2BBE cells (Panja et al., 1998; Wang et al.,
2006)], and IL-1β on PDZK1 mRNA and protein expression
as well as promoter activity in the human intestinal cell
line Caco-2BBE. IL-1β was found to significantly decrease
PDZK1 mRNA and protein expression, as well as promote
NHE3 dysfunction. Studies were therefore performed
toward the elucidation of the molecular mechanisms of
this IL-1β-induced downregulation of PDZK1 and more
importantly the question of its reversibility by pharmacological
inhibition of the different IL-1β downstream signaling
pathways.
Abbreviations: IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; IFN-
γ, interferon-γ; PDZ, PSD95, Disc-large and ZO1; PPAR α/γ, peroxisome
proliferator-activated receptor α/γ; ERK, extracellular signal-regulated kinase;
RXR α, retinoid X receptor α; JNK, c-Jun N-terminal kinase; NF-κB, nuclear
factor-κB; MAPK, mitogen-activated protein kinase; TBP, TATA-box binding
Protein; NHE3, Na+/H+ Exchanger 3; UC, ulcerative colitis.
MATERIALS AND METHODS
Reagents and Antibodies
Human recombinant IL-1β, TNF-α, and IFN-γ were purchased
from Sigma, Missouri, USA. Rabbit polyclonal PDZK1 antibody
(PAB15564) was purchased from Abnova, Taipei, Taiwan. NF-
κB inhibitor BAY11-7082 and p38MAPK inhibitor BIRB-796
were purchased from Calbiochem (Darmstadt, Germany) and
AxonMedchem (Groningen, The Netherlands) respectively. JNK
inhibitor SP600125, MEK1/2 inhibitor PD98059 and U0126
were purchased from Cell signaling Technologies, Frankfurt,
Germany.
PDZK 1 Promoter Constructs
PDZK1 promoter full length and different deletion constructs
were explained in detail previously (Tachibana et al., 2008).
Cell Culture, Seeding Density, and
Cytokine Treatment
Caco-2BBE cells were grown at 37◦C in a humidified atmosphere
containing 5% CO2 and 95% O2, in Dulbecco’s Modified Eagle
Medium containing 4.5 g·L−1 D-glucose and sodium pyruvate
supplemented with 10% FCS, 50 units penicillin/streptomycin,
and 1% non-essential amino acids. Huh-7 cells were grown in
Dulbecco’s Modified Eagle Medium containing 4.5 g·L−1 D-
glucose and sodium pyruvate supplemented with 10% FCS, 50
units penicillin/ streptomycin. 0.25 × 106 cells were plated in
6 well-plates and grown for 24 h, serum starved (0.5% FCS
in medium) for 24 h and then treated with IL-1β (0.1, 1, or
10 ng·mL−1), TNF-α (up to 20 ng·mL−1) and IFN-γ (up to
30 ng·mL−1) for the times indicated in the respective figures.
Concentration response curves for these cytokines in Caco-2BBE
cells had been tested in a previous study (Yeruva et al., 2008),
and were applied accordingly in this study. For each experiment,
two (qPCR) or three (Western Analysis) individual dishes were
studied for each experimental condition, and the results pooled
for n = 1. Each experiment was repeated three times in different
cell passages. n indicates the number of repeats in different cell
passages. Due to the homogeneity of a cell line, and the duplicate
or triplicate measurements within the same experiment, we
believe that three repeats are acceptable for a statistically valid
conclusion.
Transient Transfections and Luciferase
Assays
3 × 104 cells were seeded in 24 wells and grown overnight. Two
hundred and fifty nanograms of plasmid per well was mixed with
10 ng of renilla luciferase plasmid and transfections were done
using a Jet prime R© polyplus transfection reagent from Peqlab
(Erlangen, Germany) according manufacturer’s protocol. Cells
were serum starved overnight before adding cytokines and then
treated with cytokines for the time periods indicated in the text.
After the treatment cells were lysed in 1X passive lysis buffer
(Promega) by shaking at room temperature for 15min. Luciferase
assay was performed as described previously (Menon et al., 2011).
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Patients Selection
The details of the patients who provided the biopsies of UC
patients are given in detail in a previous report (Yeruva et al.,
2015).
Inhibition of NF-κB and MAPKs Pathways
For NF-κB and MAPK pathway inhibition experiments, Caco-
2BBE cells were pretreated with a NF-κB inhibitor BAY11-7082
(10µM), a p38MAPK inhibitor BIRB-796 (µM), a JNK inhibitor
SP600125 (25µM), MEK1/2 inhibitor PD98059 (30µM), and
U0126 (10µM) for 1 h, followed by exposure to IL-1β (10
ng·mL−1) for 48 h. Cells were lysed for Western blot analysis as
described below.
9-cis Retinoic Acid Treatment Experiments
For PDZK1 mRNA measurements, Caco-2BBE cells were
pretreated for 30 mins with 9-cis retinoic acid (RA) or vehicle
at a concentration of 1 µM and then treated with IL-1β for 3,
6, 12, and 24 h. For PDZK1 protein assessment, the cells were
pretreated with 1µMRA or vehicle for 30 min before addition of
IL-1β (10 ng·mL−1) and the cells were harvested after 48 h.
RNA Isolation and Real-Time PCRs
RNA isolation from cells was done using Qiagen RNA isolation
kit and real time PCRs were performed as explained previously
(Yeruva et al., 2015).
Immunoblot Analysis
After the treatment, cells were lysed in lysis buffer (M-PER R©
Mammalian protein extraction reagent from Thermo scientific,
Rockford, USA) and protein concentration was estimated with
Bio-rad Bradford assay. Twenty to forty micrograms of total
cellular proteins were separated on 8–10% SDS-poly acryl amide
gels and transferred to polyvinylene difluoride membranes.
Antibodies were diluted in TBST containing 5% non-fat dry
milk and blots were incubated overnight at 4◦C, washed with
TBST and incubated with secondary antibodies conjugated to
horseradish peroxidase, washed with TBST and then developed
using enhanced chemiluminescence kit from GE health sciences.
WST-1 Cell Viability Assay
The reagentWST-1 was used to determine cell viability according
to the manufacturer’s instructions. In brief, Caco-2BBE cells were
seeded at a density of 1 × 104 cells in each well of a 96 well-plate
and were grown and treated as stated in the section “Cell culture,
seeding density, and cytokine treatment.” Cells were incubated
with respective cytokines for 24 h. At the end of treatment, 10
µl WST-1 were added to each well and 1 h later absorbance
was measured at 450 and 630 nm using the BioTek R© Epoch
Reader. No decrease in viability was detected during exposure of
any of the tested cytokines or their combination (Supplementary
Figure 5).
Statistical Analysis
Results are given as means ± SEM (Standard error of mean).
We usually performed 3–4 independent experiments in different
passages of cells, where individual data points were based on
at least triplicates for each condition. Unpaired Student’s two-
tailed t-test were used for comparing between two groups.
One or Two-way analysis of variance (ANOVA) with post-
hoc analysis including Dunnett’s Multiple Comparison Test and
Bonferroni post-tests were used for multiple comparisons. All
analyses were performed on GraphPad Prism version 6.0 and
P < 0.05 were considered significant. ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001.
RESULTS
Interleukin-1β Strongly Down Regulates
PDZK1 mRNA and Protein Expression as
Well as PDZK1 Promoter Activity in
Caco-2BBE Cells in a Concentration- and
Time-Dependent Manner
Caco-2BBE cells were treated with IL-1β (10 ng·mL−1),
TNF-α (20 ng·mL−1), and IFN-γ (30 ng·mL−1), alone or
in combination and effects on PDZK1 mRNA and protein
expression were assessed after 24 h of incubation. IL-
1β had the strongest inhibitory effect on PDZK1 mRNA
expression (Figure 1A), and was the only tested cytokine
which significantly decreased protein expression at that
time point (Figures 1B,C). The combination of all three
cytokines did not show a stronger inhibition of PDZK1 gene
expression than IL-1β alone and the effect of TNF-α and/or
IFN-γ on PDZK1 mRNA expression did not reach the level
of significance at 24 h exposure time (Figure 1A). The full
length PDZK1 promoter containing luciferase reporter plasmid
(pPDZK1-4689) displayed robust basal promoter activity
in Caco-2BBE cells (26.8 ± 6.3-fold increase of luciferase
activity compared to vector backbone expression), which
was significantly decreased in the presence of 10 ng·mL−1
IL-1β (Figure 1D). Treatment of Caco-2BBE cells with either
TNF-α or IFN-γ did not result in significant inhibition, and
the combination or all the three cytokines together did not
cause a stronger inhibition than IL-1β alone (14.5 ± 2.8-
fold with IL-1β vs. 10.0 ± 1.7-fold with the cytomix, ns;
Figure 1D).
The effect of IL-1β on PDZK1mRNA (Figure 2A) and protein
expression (Figures 2B,C) as well as PDZK1 promoter activity
(Figure 2D) was concentration-dependent, with a maximal
inhibition of PDZK1 mRNA expression to 30.3 ± 10.6%
of the value of vehicle treated controls at 10 ng·mL−1 IL-
1β, and of PDZK1 protein expression to 42.6 ± 10% at
10 ng·mL−1 IL-1β. Treatment of Caco-2BBE cells with IL-
1β (one single addition at time 0) for 6, 12, and 24 h
revealed that PDZK1 mRNA expression was significantly
downregulated within 12 h after 10 ng·mL−1 IL-1β addition
to 43.8 ± 13.2% of vehicle-treated controls, and remained
downregulated after 24 h (Figure 3A). The effect of IL-1β
on PDZK1 protein expression was not significant at 12 h,
whereas by 24 h IL-1β had a strong inhibitory effect to
52.2 ± 12.6% and this inhibitory effect was persistent at
48 h (50.9 ± 6.3% of vehicle-treated control value, n = 3;
Figures 3B,C). We also studied the effect of the same cytokines
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FIGURE 1 | Cytokine mediated regulation of PDZK1 in Caco-2BBE cells. (A) PDZK1 mRNA expression in Caco-2BBE cells was analyzed by real-time PCRs
after treatment with IL-1β (10 ng·mL−1 ), TNF-α (20 ng·mL−1 ), and IFN-γ (30 ng·mL−1 ) alone or in combination, data are represented as fold change in expression
normalized to TBP. (B) PDZK1 protein expression was analyzed by Western blots using β-actin as a loading control. (C) Western quantification using image J
software. Among the treated cytokines, IL-1β leads to more than a 50% decrease in PDZK1 mRNA and protein expression. Bar graphs are represented as mean ±
SEM. *indicates P < 0.05 and **indicates P < 0.01 compared to control, n = 4 experimental repeats in different passages. (D) PDZK1 promoter activity was
normalized to the pGVB (vector backbone) transfected control cells and shown as relative fold change. Among the different cytokine treatments IL-1β alone had
strong inhibition of PDZK1 promoter activity. Bar graphs are represented as mean ± SEM. ***P < 0.001 compared to vector back bone and #P < 0.001 compared to
control. n = 4 experimental repeats done in triplicates for each condition.
on PDZK1 expression in the hepatoma cell line Huh-7,
which also express PDZK1. Treatment with IL-1β led to a
significant decrease of PDZK1 protein expression in Huh-
7 cells (45.8 ± 2.2% of controls; Supplementary Figure 1),
suggesting that a more general signaling pathway, rather
than enterocyte-specific mediators are involved in PDZK1
downregulation.
The 5′ End of the PDZK1 Promoter is
Important for Basal Activity and IL-1β
Downregulation of Promoter Activity
Transient transfections of PDZK1 promoter 5′-deletion reporter
constructs in Caco-2BBE cells revealed that deletion of base
pairs –4689 to –3995 led to a strong decrease of basal PDZK1
promoter activity by 80.2% of that of the full length promoter,
and a significant loss of IL-1β mediated inhibition (Figure 4).
This region harbors numerous transcription factor binding
sites, which in part are known downstream targets for IL-
1β-receptor-activated kinases (see next paragraph), as well as
the retinoic acid response element (RARE; Supplementary
Figure 2).
Effect of Blocking IL-1β Receptor
Downstream Signaling Pathways on the
Inhibition of PDZK1 Expression by IL-1β
IL-1β receptor activation exerts its cellular effects via several
downstream pathways, including NF-κB, p38MAPK, ERK1/2,
and JNK pathways (Weber et al., 2010). The most specific
inhibitors for the respective signaling pathways were selected
(Davies et al., 2000; Bain et al., 2003, 2007) and tested in various
concentrations for their ability to attenuate the effect of IL-
1β on PDZK1 protein expression. Pre-treatment with 10 µM
of the NF-κB inhibitor BAY11-7082, 1 µM of the p38MAP
kinase inhibitor BIRB-796 (Figures 5A,B) and 25 µM of the
JNK1-3 inhibitor SP600125 did not significantly diminish the
effect of IL-1β on PDZK1 protein expression (Figures 5C,D).
In contrast, inhibition of the ERK1/2-cascade by two different
MEK-inhibitors, namely PD98059 (Figures 5C,D) and U0126
(Figures 5E,F), both significantly stimulated PDZK1 expression
to 144.6± 5.1% of vehicle-treated control for PD98059, and 153.7
± 13.8% of vehicle-treated control for U0126 and significantly
attenuated the IL-1β-induced PDZK1 downregulation (53.2 ±
4.1% inhibition in the absence vs. 28.1 ± 7.4% in the presence
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FIGURE 2 | Dose dependent downregulation of PDZK1 mRNA and protein expression as well as PDZK1 promoter activity in IL-1β treated Caco-2BBE
cells. (A) PDZK1 mRNA expression in Caco-2BBE cells was analyzed by real-time PCRs after treatment with increased concentration of IL-1β (0.1, 1, 10 ng·mL−1),
data are represented as fold change in expression normalized to TBP. (B) PDZK1 protein expression was analyzed by Western blots using β-actin as a loading control.
(C)Western quantification using image J software. IL-1β downregulated PDZK1 protein expression in a dose dependent manner. Bar graphs are represented as mean
± SEM. *indicates P < 0.05 and **indicates P < 0.01 compared to control, n = 4 experimental repeats in different passages. (D) Dose dependent inhibition of PDZK1
promoter activity by IL-1β in Caco-2BBe cells. Bar graphs are represented as mean ± SEM. **indicates P < 0.01 and ***indicates P < 0.001. n = 3 experimental
repeats done in triplicates for each condition.
of PD98059, p < 0.05, n = 3, and 53.6 ± 5.3% inhibition in the
absence vs. 29.6 ± 3.1% in the presence of 10 µM U0126, p <
0.05, n= 3).
Effect of Retinoic Acid on PDZK1
Expression
9 cis-retinoic acid (RA), a ligand for both RAR and RXR
receptors, increased PDZK1 mRNA expression levels in Caco-
2BBE cells 3 h after application (Figure 7A). qPCR analysis
revealed that RXR-α mRNA expression was significantly
decreased in intestinal mucosa of patients with active ulcerative
colitis (Figure 6A). It was also significantly decreased 12 h
after IL-1β addition to Caco-2BBE cells, with restoration to
preincubation levels after 24 h (Figure 6B). This suggests
that an IL-1β-mediated RXR-α depression may be involved
in inflammation-associated PDZK1 downregulation. We tested
whether the inhibitory effect of IL-1β on PDZK1 protein
expression was, in part, reversible by simultaneous RA
application. RA resulted in a significant increase of PDZK1
mRNA at 12 h (Figure 7A), and protein expression at 24 h
(Figures 7B,C) both in the absence and presence of IL-1β.
PDZK1 mRNA and protein expression was restored to control
levels after co-administration of both substances. Figure 7A
displays the different time dynamics of the effect of RA and IL-
1β on PDZK1 mRNA expression, with a rapid but less sustained
action of RA than of IL-1β. Twenty-four hours after the addition
of both substances, the percentage-inhibitory effect of IL-1β on
PDZK1 expression was 32.9 ± 8.7% in the absence and 9.4 ±
29.3% in the presence of RA at the mRNA level, and was 49.9
± 3.8% in the absence and 28.5 ± 4.0% in the presence of RA at
the protein level (Figures 7A–C).
Effect of the PPARα Agonist GW7647 on
PDZK1 Expression
The transcription factor peroxisome proliferator-activated
receptor alpha (PPARα) has been identified as a strong activator
of the PDZK1 promoter (Tachibana et al., 2008). The peroxisome
proliferator response element, to which the heterodimer PPARα
and RXRα binds, is not located in the 5′ end of the PDZK1
promoter, but close to the start of transcription site at 98–86 bp,
thus, not in the region sensitive to IL-1ß. Interestingly, IL-1β
incubation also decreased PPARα expression in Caco2BBE cells
to 65.5 ± 9.6% at 24 h incubation (Supplementary Figure 4),
whereas a significant effect on PDZK1 mRNA expression was
Frontiers in Physiology | www.frontiersin.org 5 February 2017 | Volume 8 | Article 61
Luo et al. Cytokine-Mediated PDZK1 Downregulation
FIGURE 3 | Time kinetics of IL-1β mediated PDZK1 downregulation in Caco-2BBE cells. (A) PDZK1 mRNA expression was analyzed by real-time PCRs in
Caco-2BBE cells in the presence of 10 ng·mL−1 of IL-1β at different time points (6, 12, and 24 h) and data are represented as fold change in expression normalized to
TBP. (B,C) PDZK1 protein expression was analyzed by Western blots in Caco-2BBE cells in the presence of 10 ng·mL−1 of IL-1β at different timepoints (12, 24, and
48 h). Bar graphs are represented as mean ± SEM. **indicates P < 0.01 compared to control, n = 4 experimental repeats in different passages, done in triplicates for
each condition.
seen earlier (Figure 3A). It is nevertheless feasible that a PPARα
agonist is able to restore PDZK1 expression in pro-inflammatory
settings, offering a window for pharmacological intervention.
We therefore incubated Caco2BBE cells with the PPARα agonist
GW7647, in the absence and presence of IL-1β. At 24 h after
GW7647 application, resulted in a significant increase of PDZK1
protein expression to 129.7 ± 6.5% of vehicle treated control
(Figures 8A,B), and GW7647 was able to attenuate the IL-1β-
mediated decrease in PDZK1 expression (61.1 ± 3.4% in the
absence and 33.9± 2.3% in the presence of GW7647).
DISCUSSION
This study investigated the effect of three cytokines IL-1β,
TNF-α, and IFN-γ on PDZK1 gene expression in Caco-2BBE
cells, since these cytokines were known to be released in the
mucosa of IBD patients (Reinecker et al., 1993; Dionne et al.,
1997; Raddatz et al., 2005; Matsuda et al., 2009; Yeruva et al.,
2010, 2015). We found that IL-1β strongly decreased PDZK1
promoter activity, mRNA and protein expression, whereas even
high concentrations of the other two Th1 cytokines did not have
a significant inhibitory effect. Since it is difficult to mimic the
constant release of cytokines from immune cells in the lamina
propria in an in vitro experimental setting, the experiments
do not completely rule out a role for the tested, as well as
other cytokines, on PDZK1 expression in vivo. Since we had
found IL-1β expression 10-fold upregulated in the mucosa of
patients with moderately active chronic ulcerative colitis under
treatment compared to inactive colitis, whereas the other two
cytokines were only ∼2-fold upregulated in this chronic stage
(Yeruva et al., 2010, 2015), IL-1β seemed a pathophysiologically
meaningful target molecule for further investigation. PDZK1
was found strongly downregulated in the same mucosal tissues
(Yeruva et al., 2015). IL-1β was also strongly upregulated
and PDZK1 strongly downregulated in inflamed murine liver
(Sharma, unpublished results), and indeed IL-1β had a similar
effect on PDZK1 expression in hepatocytes as in enterocytes
(Supplementary Figure 1). Therefore, IL-1β seemed a likely,
although not necessarily an exclusive mediator of, inflammation-
induced decrease in PDZK1 expression.
IL-1β exerted a relatively slow and surprisingly long-lasting
effect on PDZK1 mRNA expression with a maximum effect
12 and 24 h after addition to the medium of the Caco-2BBE
cells, and on PDZK1 protein expression at 24 and 48 h.
Because approx. one third of IBD patients maintain mucosal
inflammation and suffer from inflammatory diarrhea despite
appropriate anti-inflammatory treatment, we asked the question
whether the PDZK1 downregulation can be attenuated by
inhibiting IL-1β receptor downstream signaling pathways. The
IL-1β receptor was shown to influence gene expression by
a number of signaling pathways, the best known being NF-
κB, p38MAPK, JNK, and ERK1/2 cascades. In a previous
study in Caco2 cells investigating IL-1β-stimulated chemokine
expression, IL-1β was found to act majorly through NF-κB and
p38MAPK pathways (Yeruva et al., 2008). Surprisingly, neither
of these pathways seems responsible for the IL-1β mediated
suppression of PDZK1. Inhibition of NF-κB signaling with
BAY11-7082, which had been previously shown to inhibit IL-
1β induced chemokine expression in Caco2 cells (Yeruva et al.,
2008), did not significantly influence the downregulation of
PDZK1 protein levels (Figure 5) or promoter activity by IL-
1β (Supplementary Figure 3). Instead, we observed a decrease
Frontiers in Physiology | www.frontiersin.org 6 February 2017 | Volume 8 | Article 61
Luo et al. Cytokine-Mediated PDZK1 Downregulation
FIGURE 4 | Identification PDZK1 promoter region important for basal expression and IL-1β responsiveness. Caco-2BBE cells were transiently transfected
with a series of 5′-deletion PDZK1 promoter constructs and treated with and without IL-1β (10 ng·mL−1 ) for 24 h. Cells were harvested and luciferase assays were
performed as described in materials and methods. IL-1β responsiveness and basal promoter activity was abolished after the deletion of the PDZK1 promoter region
between 5′ 4689 and 3995 bp. Bar graphs are represented as mean ± SEM. *indicates P < 0.001 pGVB compared to pPDZK1-4689, $indicates P < 0.001 IL-1β
compared basal and §indicates P < 0.001, pPDZK1-4689 compared to the rest of deletion constructs. n = 3 experimental repeats, done in triplicates for each
condition.
in the basal PDZK1 protein expression as well as promoter
activity on BAY11-7082 treatment, suggesting that either NF-
κB pathway is required for basal PDZK1 promoter activity or
that BAY11-7082 exerted effects not directly related to NF-
κB inhibition. Interestingly, a recent report has shown that
the mode of action of BAY11-7082 involves inhibition of the
ubiquitin conjugation machinery, leading to off-targets including
the HIF-1α signaling pathway (Strickson et al., 2013). The
fact that TNF-α stimulation resulted in a marked increase
of NF-κB activity in Caco-2BBE cells (Musch et al., 2001;
Carlson et al., 2007), but did not significantly decrease PDZK1
expression (this manuscript), corroborates the independence of
IL-1β-mediated PDZK1 downregulation from NF-κB activation.
While p38MAPK signaling is crucial for the pro-inflammatory
cytokine gene-expression downstream to IL-1 signaling, the
specific p38MAPK inhibitor BIRB-796 (Bain et al., 2007; Menon
et al., 2011), did not attenuate the IL-1β-mediated decrease
in PDZK1 protein expression or promoter activity (Figure 5).
Moreover, a role for the stress-activated JNK-signaling was also
ruled out, since the JNK1-3 inhibitor SP600125 neither affected
basal expression nor rescued IL-1β-mediated downregulation
of PDZK1. Interestingly, the MEK inhibitor PD98059, which
inhibits the ERK1/2 (and ERK5) pathway, both increased basal
PDZK1 expression in Caco-2BBE cells and diminished the
relative decrease of PDZK1 expression by IL-1β (Figure 5D).
To confirm the role of the ERK pathway signaling on PDZK1
expression we used U0126, another MEK inhibitor claimed to
be specific for this pathway (Davies et al., 2000; Nishimoto
and Nishida, 2006), and obtained similar effects (Figure 5F),
suggesting that the ERK pathway negatively regulates PDZK1
expression. ERK activation inhibits differentiation in Caco-
2BBE as well as other intestinal cell lines (Lemieux et al.,
2011), and may do so in part by negatively regulating the
expression of the differentiation marker PDZK1. While the
results demonstrate that ERK inhibition at the level of the
epithelial cells can reverse the negative effect of proinflammatory
cytokine signaling on adaptor protein expression and thereby
transport function, it is unlikely that a therapeutic strategy
can be developed based on the inhibition of such a globally
important signaling pathway. We therefore searched for
potential targets for which inhibitor strategies are already in
clinical use.
The region of the PDZK1 promoter between –4689 and
–3995 bp was found to be important for both a major
part of basal promoter activity as well as responsiveness
to IL-1β. An in silico analysis of this region showed a
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FIGURE 5 | Effects of NF-kB, p38-MAPK, JNK, and ERK 1/2 inhibitors on PDZK1 protein expression. (A). Caco-2BBE cells were pre-treated for 1 h with
BAY11-7082 (10 µM) and BIRB-796 (1 µM) alone and in combination and then treated for 48 h with IL-1β (10 ng·mL−1). PDZK1 protein expression was analyzed by
Western blots using β-actin as a loading control. (B) Western quantification using image J software. Both the inhibitors either used alone or in combination couldn’t
reverse the effect of IL-1β on PDZK1 protein expression. (C) However, pre-treatment of Caco-2BBe cells with JNK1-3 (25 µM of SP600125) and ERK1/2 (30 µM of
PD98059) signal pathways inhibitor (C,D) revealed the involvement of ERK1/2 pathway in IL-1β mediated PDZK1 downregulation. PDZK1 protein expression was
analyzed by Western blots using β-actin as a loading control. (D) Western quantification using image J software. JNK1-3 inhibitor SP600125 couldn’t diminish the
effect of IL-1β on PDZK1 protein expression. ERK1/2 inhibition by PD98059 stimulated PDZK1 expression and attenuated the IL-1β-induced PDZK1 downregulation.
(E) Caco-2BBE cells were pretreated for 1 h with ERK 1/2 inhibitor U0126 (10 µM) before IL-1β (10 ng·mL−1) treatment for 48 h. PDZK1 protein expression was
analyzed by Western blots using β-actin as a loading control. (F) Western quantification using image J software. U0126 could reverse the effect of IL-1β on PDZK1
protein expression. Bar graphs are represented as mean ± SEM. *indicates P < 0.05 and **indicates P < 0.01. n = 3 experimental repeats in different cell passages,
triplicate cell dishes for each experimental condition.
variety of putative transcription factor binding elements,
among them the retinoic acid response element (RARE;
Supplementary Figure 2). Indeed, 9-cis retinoic acid (RA),
a ligand for both nuclear receptors RAR and RXR, caused
a rapid increase in PDZK1 mRNA expression within 3
h (Figure 7A), followed by an increase in PDZK1 protein
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FIGURE 6 | RXR-α mRNA expression analysis from UC patients and Caco-2BBE cells. (A) RXR-α mRNA expression in biopsies of ulcerative colitis patients
which were used in our previous study. A geometrical mean of two housekeeping genes (TBP and β-actin) were used as normalization controls as explained in our
previous study (Yeruva et al., 2010). (B) RXR-α mRNA expression in Caco-2BBE cells treated with and without IL-1β for different time points (6, 12, and 24 h) as
depicted in the bar graph. IL-1β significantly downregulated RXR-α mRNA levels by 12 h. n = 3 experimental repeats done in duplicates for each condition. Bar
graphs are represented as mean ± SEM. *indicates P < 0.05 compared to control.
FIGURE 7 | 9-cis retinoic acid (RA) attenuated IL-1β induced PDZK1 protein downregulation. (A) Caco-2BBE cells were pre-treated for 1 h with 9-cis retinoic
acid (RA) at a concentration of 1 µM and before IL-1β (10 ng·mL−1 ) for treatment at different time pint (3, 6, 12, and 24 h). Cells were harvested after the treatment for
RXR-α mRNA analysis. Treatment with RA clearly abrogated the IL-1β mediated PDZK1 down regulation. n = 3 experimental repeats done in duplicates (different cell
dishes) for each condition. Bar graphs are represented as mean ± SEM. *indicates p < 0.05 compared to control. (B) Caco-2BBe cells were pre-treated with RA (1
µM) and then treated with IL-1β (10 ng·mL−1 ) for 48 h before lysing the cells for protein expression study. Western blot analysis of PDZK1 protein expression and
(C) Image J quantification of the blots normalized to β-actin expression. Treatment with RA clearly abrogated the IL-1β mediated PDZK1 down regulation in
Caco-2BBE cells. Bar graphs are represented as mean ± SEM. n = 3 experimental repeats in different passages, done in triplicates for each condition. Bar graphs
are represented as mean ± SEM. *indicates P < 0.05 and **indicates P < 0.01.
expression (Figures 7B,C). In addition, RA and IL-1β co-
incubation decreased the percentage of the IL-1β-induced
decrease in PDZK1 mRNA and protein expression up to 48 h
after addition (Figure 7). Since it has been previously shown
that IL-1β decreases the expression of RXRα in liver cells
(Li et al., 2002; Kim et al., 2007), and because RXRα was
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FIGURE 8 | Effects of PPARα agonist (GW7647) on PDZK1 protein
expression. (A) Caco-2BBE cells were pre-treated for 1 h with PPARα
agonist GW7647 at a concentration of 1 µM and then treated with IL-1β (10
ng·mL−1) in Caco-2BBE cells for an additional 48 h. Cells were harvested
after the treatment for protein isolation. Western blot analysis of PDZK1 protein
expression and (B) Image J quantification of the blots normalized to β-actin
expression. Treatment with GW7647 clearly abrogated the IL-1β mediated
PDZK1 down regulation. Bar graphs are represented as mean ± SEM.
*indicates P < 0.05 and **indicates P < 0.01. n = 3 experimental repeats,
done in triplicates for each condition.
found to be downregulated in the liver during acute phase
responses (Beigneux et al., 2000), we studied RXRα mRNA
expression in colonic biopsies from UC patients and in Caco-
2BBE cells after IL-1β treatment, and found a decrease in
both (Figure 6). Interestingly, RXRα is a direct substrate of
ERK1/2, and ERK-mediated phosphorylation suppresses its
transactivation potential (Solomon et al., 1999), suggesting that
both direct posttranslational modification of RXRα by ERK1/2
and downregulation of its expression by IL-1β, downstream
signaling could contribute to the suppression of PDZK1
expression. Despite the inhibitory effect of IL-1β on RXRα-
expression and possibly transactivation, RA was able to increase
PDZK1 levels in the presence of IL-1β, opening a window for
therapeutic intervention.
The PDZK1 promoter also contains a peroxisome proliferator
response element (PPRE), to which PPARα binds as a
heterodimer with RXRα (Tachibana et al., 2008). This response
element is not in the part of the promoter that was most
sensitive to IL-1β, but was close to the transcription start site (see
Section Results). A reduced PPARα as well as PPARγ expression
has been described in UC patient biopsies (Yamamoto-Furusho
et al., 2011). Since the PPARα agonist GW7647 increased
PDZK1 expression in Huh-7 hepatoma cells (Tachibana et al.,
2008), as well as in Caco-2BBE cells (Figure 8), it is possible
that the positive effect of RA on PDZK1 expression exerts
its effect via binding of RXRα to the PPRE element as well
as the RARE element. We wondered if the activation of the
PPRE element by GW7647 may have a positive effect PDZK1
expression in the presence of IL-1β, and indeed GW7647 was
also able to attenuate the inhibitory effect of IL-1β on PDZK1
expression.
PPARα dependent signaling pathways have been claimed
to be involved both in the exacerbation (Qi et al., 2014)
and the attenuation of colitis, the latter via enteric glia
(Esposito et al., 2014). PPARγ also forms heterodimers with
RXRα, and anti-inflammatory effects and amelioration of
experimental colitis has been described with a number of
PPARγ agonists through trans-repression of signal-dependent
transcription factors that mediate inflammatory programs of
gene activation (Linard et al., 2008). 5-ASA, the oldest and
most widely used drugs in the treatment of inflammatory bowel
diseases, is a PPAR agonist, but has many other inhibitory effects
on inflammatory pathways (Perrotta et al., 2015). Many other
PPAR agonists are in clinical use and novel ones are being
tested.
In summary, IL-1β strongly downregulated PDZK1
expression in an ERK-dependent fashion in the intestinal
cell line Caco-2BBE, demonstrating that the strong
decrease in this important adaptor protein in inflamed
intestine is a cytokine-mediated event and is attenuated
by inhibiting MEK-dependent ERK activation. Stimulation
of the nuclear receptors RXRα and PPARα increased
PDZK1 expression, and attenuated the IL-1β induced
downregulation. It may thus be possible to revert
inflammation-induced epithelial damage and improve
absorptive function even in the presence of ongoing cytokine
release.
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